Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy plus pembrolizumab after progression on prior PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer
KCT0005824Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Oct 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on KCT0005824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005824.